Somatostatin receptors are an important target for medical treatment of pituitary and neuroendocrine tumors. To date, five somatostatin receptor (sst) subtypes have been identified. The currently available somatostatin analogues octreotide and lanreotide have predominantly affinity for sst2. Pasireotide is a sst multireceptor ligand with affinity for sst1 , sst2, sst3 and sst5 and this broader binding profile may translate into a higher efficacy with respect to suppression of hormone production and cell growth in certain tumors. Experimental animal studies and in vitro studies with cultured tumor cells have shown that pasireotide strongly suppresses growth hormone and adrenocorticotropin productioN. In addition, pasireotide can influence tumor cell growth via effects on apoptosis and angiogenesis. In this review, the role of somatostatin receptors in pituitary and neuroendocrine tumors is briefly discussed followed by an overview of possible applications of pasireotide based on recent trials in patients with acromegaly, Cushing's disease and neuroendocrine tumors. Copyright

Additional Metadata
Keywords Cushing's disease, Growth hormone release inhibitors, Pasireotide, SoM-230
Persistent URL dx.doi.org/10.1358/dot.2013.49.2.1915142, hdl.handle.net/1765/74671
Journal Drugs of Today
Citation
Feelders, R.A, de Herder, W.W, Neggers, S.J.C.M.M, van der Lely, A-J, & Hofland, L.J. (2013). Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs of Today, 49(2), 89–103. doi:10.1358/dot.2013.49.2.1915142